My name is Julia Stingl.
Former name was Kirchheiner.
I am a Professor of Clinical Pharmacology at the University Bonn.
And I will talk about clinical importance
of pharmacogenetic polymorphisms affecting drug metabolism.
Part 2, Internal Medicine.
We have now more than 30 years of pharmacogenetic research.
But still we may ask ourselves, do we really use it?
Where is the translation into the clinics?
And these are the questions that are most urgent.
What is the patient's benefit?
And how could we increase drug safety with the use of pharmacogenetics?
Or has our drug therapy been improved by genetic diagnostics?
So to come closer to an answer of these questions,
I would like to talk about pharmacogenetics
in internal medicine and, first, give you a short introduction
to the pharmacogenetics variants impacting drug therapy in internal medicine.
There are genetic polymorphisms affecting both sides of drug action,
pharmacokinetics or pharmacodynamics.
On the pharmacokinetics side, mostly drug metabolism and elimination
is affected, and this can be translated into clinical practice
by giving, for example, dose adjustments.
This can affect the dose amount or the dosing interval.
Whereas on the pharmacodynamic side, genetic variants in drug targets,
they may be translated into the clinics,
for example with companion diagnostic molecular diagnostics.
It may improve therapeutic strategies.
Or it may lead to treatment algorithms.